NCT04831944

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Parsaclisib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal hepatic function and participants with hepatic impairment.

Conditions

• Advanced Malignancies

Interventions

Type	Name	Description
DRUG	parsaclisib	parsaclisib will be administered orally after 8 hours of fasting.

Timeline

• Start date: 2021-03-29
• Primary completion: 2022-03-10
• Completion: 2022-03-11
• First posted: 2021-04-05
• Last updated: 2022-08-26

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study